Bavarian's market value up USD 1bn over three days

Over the course of three days, Bavarian Nordic has seen its share price increase by around DKK 100 (USD 14.3).


Everyone wants a slice of Bavarian Nordic following the widely reported small outbreak of monkeypox in a number of countries around the world.

This has turned the spotlight on Bavarian, which has the only approved vaccine against the disease – and which signed a supply deal with an undisclosed European country last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs